Regulatory bodies are expected to protect the public from the danger of inappropriately tested treatments—a shield against the vested interest of drug and device companies to sell products irrespective of their safety and effectiveness. The idea of the greedy industrialist focused on short term advantage and endangering lives with low quality components used to save manufacturing costs is familiar to the public and seems to justify stringent regulatory processes. But one person is forgotten in this equation—the doctor.
Commentary: The risk of over-regulation / Di Mario C.; James S.; Dudek D.; Sabate M.; Degertekin M.. - In: BMJ. - ISSN 1756-1833. - ELETTRONICO. - 342:(2011), pp. d3021-d3021. [10.1136/bmj.d3021]
Commentary: The risk of over-regulation
Di Mario C.
;
2011
Abstract
Regulatory bodies are expected to protect the public from the danger of inappropriately tested treatments—a shield against the vested interest of drug and device companies to sell products irrespective of their safety and effectiveness. The idea of the greedy industrialist focused on short term advantage and endangering lives with low quality components used to save manufacturing costs is familiar to the public and seems to justify stringent regulatory processes. But one person is forgotten in this equation—the doctor.File | Dimensione | Formato | |
---|---|---|---|
bmj.d3021.full.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
139.02 kB
Formato
Adobe PDF
|
139.02 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.